NRIX (Nurix Therapeutics Inc) רווח למניה בארבעת הרבעונים האחרונים

Nurix Therapeutics (NRIX) is establishing a cutting-edge targeted protein degradation environment to combat oncology. The annual EPS (TTM) change reflects the dynamics of this process, while the 185.40 value indicates the yield status. Development relies on extensive outsourcing of late-stage testing, with the overall system's stability directly dependent on strict FDA safety regulations.
Nurix Therapeutics Inc - פילוחים אנליטיים ומדדי מפתח (NRIX)

This indicator measures the rate of change in earnings per share over a rolling twelve-month period, allowing for an assessment of value generation efficiency relative to the market price. For Nurix Therapeutics (NRIX), the EPS YoY TTM percentage trend reflects the business's resilience to geopolitical risks within component supply chains and patent disputes, revealing the company's actual strength relative to the sector.